# Safety of MT-401-OTS in Patients With Relapsed AML or MDS

> **NCT06552416** · PHASE1 · RECRUITING · sponsor: **Marker Therapeutics, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- MDS

## Interventions

- **DRUG:** MT-401-OTS

## Key facts

- **NCT ID:** NCT06552416
- **Lead sponsor:** Marker Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06552416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06552416, "Safety of MT-401-OTS in Patients With Relapsed AML or MDS". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06552416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*